BRACAnalysis® Breast Cancer
BRACAnalysis® is a genetic test that detects the presence of a BRCA1 or BRCA2 gene mutation. The results of the BRACAnalysis test enable the development of patient-specific medical management plans to significantly reduce the risk of cancer. Additionally, this information can help inform treatment decisions related to PARP inhibitor therapy.1
Inform Treatment Decisions
- Knowing BRCA1 and BRCA2 status may inform treatment decisions related to PARP inhibitors
- In the OlympiAD trial of patients with HER2-negative metastatic breast cancer and a germline BRCA mutation, the risk of progression or death was 42% lower with olaparib monotherapy than with standard therapy1
Manage Future Cancer Risk
- If BRACAnalysis® testing identifies the presence of a BRCA1 or BRCA2 mutation, medical management options may help reduce cancer risk and may either delay the onset of cancer, detect cancer at an earlier, more treatable stage or even prevent it.
- First-degree relatives of these patients are at a 50% risk for carrying the mutation.
- Those relatives who are positive may benefit from increased surveillance and/or preventive measures.
In the OlympiAD Trial, in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation, olaparib monotherapy provided a significant benefit over standard therapy by reducing the risk of disease progression or death by 42%.
This practice-changing evidence highlights the need for the identification and testing of all appropriate patients for hereditary breast cancer to identify the BRCA mutation carriers in order to inform therapeutic decisions. Additionally, studies such as TNT and GeparSixto highlight the clinical utility of knowing BRCA1/2 status in patients when making treatment decisions related to DNA-damaging chemotherapy.
Explore these publications to learn more about how BRCA1/2 can impact treatment decisions related to PARP inhibitor therapy and DNA-damaging chemotherapy.
* BRACAnalysis CDx has been approved by the FDA for patients with breast and ovarian cancer who are or may become eligible for treatment with the PARP inhibitor Lynparza® (olaparib). BRACAnalysis CDx can also identify patients with ovarian cancer who may experience enhanced progression-free survival (PFS) from Zejula® (niraparib) maintenance therapy. myRisk, myChoice HRD and BRACAnalysis have not been reviewed or approved by the FDA.1,2
- Robson et al. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. N Engl J Med (2017). 377:523-533